PandemieGrippaleV1, Pmc, Corpus, bibRecord, 000825

Vaccine approaches conferring cross-protection against influenza viruses

Identifieur interne : 000825 ( Pmc/Corpus ); précédent : 000824; suivant : 000826

Vaccine approaches conferring cross-protection against influenza viruses

Auteurs : Sai V. Vemula ; Ekramy E. Sayedahmed ; Suryaprakash Sambhara ; Suresh K. Mittal

Source :

Expert review of vaccines [ 1476-0584 ] ; 2017.

RBID : PMC:6005355

Abstract

Introduction

Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of currently available influenza vaccines are strong inducer of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants.

Areas covered

Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have potential to provide broad spectrum protection against influenza viruses.

Expert opinion

Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005355

DOI: 10.1080/14760584.2017.1379396
PubMed: 28925296
PubMed Central: 6005355

Links to Exploration step

PMC:6005355

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccine approaches conferring cross-protection against influenza viruses</title>
<author><name sortKey="Vemula, Sai V" sort="Vemula, Sai V" uniqKey="Vemula S" first="Sai V." last="Vemula">Sai V. Vemula</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sayedahmed, Ekramy E" sort="Sayedahmed, Ekramy E" uniqKey="Sayedahmed E" first="Ekramy E" last="Sayedahmed">Ekramy E. Sayedahmed</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sambhara, Suryaprakash" sort="Sambhara, Suryaprakash" uniqKey="Sambhara S" first="Suryaprakash" last="Sambhara">Suryaprakash Sambhara</name>
<affiliation><nlm:aff id="A2">Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K." last="Mittal">Suresh K. Mittal</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">28925296</idno>
<idno type="pmc">6005355</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005355</idno>
<idno type="RBID">PMC:6005355</idno>
<idno type="doi">10.1080/14760584.2017.1379396</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000825</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000825</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Vaccine approaches conferring cross-protection against influenza viruses</title>
<author><name sortKey="Vemula, Sai V" sort="Vemula, Sai V" uniqKey="Vemula S" first="Sai V." last="Vemula">Sai V. Vemula</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sayedahmed, Ekramy E" sort="Sayedahmed, Ekramy E" uniqKey="Sayedahmed E" first="Ekramy E" last="Sayedahmed">Ekramy E. Sayedahmed</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sambhara, Suryaprakash" sort="Sambhara, Suryaprakash" uniqKey="Sambhara S" first="Suryaprakash" last="Sambhara">Suryaprakash Sambhara</name>
<affiliation><nlm:aff id="A2">Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K." last="Mittal">Suresh K. Mittal</name>
<affiliation><nlm:aff id="A1">Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Expert review of vaccines</title>
<idno type="ISSN">1476-0584</idno>
<idno type="eISSN">1744-8395</idno>
<imprint><date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Introduction</title>
<p id="P3">Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of currently available influenza vaccines are strong inducer of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants.</p>
</sec>
<sec id="S2"><title>Areas covered</title>
<p id="P4">Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have potential to provide broad spectrum protection against influenza viruses.</p>
</sec>
<sec id="S3"><title>Expert opinion</title>
<p id="P5">Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <pmc-dir>properties manuscript</pmc-dir>
  <front><journal-meta><journal-id journal-id-type="nlm-journal-id">101155475</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30416</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Rev Vaccines</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Rev Vaccines</journal-id>
<journal-title-group><journal-title>Expert review of vaccines</journal-title>
</journal-title-group>
<issn pub-type="ppub">1476-0584</issn>
<issn pub-type="epub">1744-8395</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">28925296</article-id>
<article-id pub-id-type="pmc">6005355</article-id>
<article-id pub-id-type="doi">10.1080/14760584.2017.1379396</article-id>
<article-id pub-id-type="manuscript">NIHMS974409</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Vaccine approaches conferring cross-protection against influenza viruses</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Vemula</surname>
<given-names>Sai V.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">3</xref>
<xref ref-type="author-notes" rid="FN3">§</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sayedahmed</surname>
<given-names>Ekramy E</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN3">§</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sambhara</surname>
<given-names>Suryaprakash</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Mittal</surname>
<given-names>Suresh K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Department of Comparative Pathobiology, and Purdue Institute for Immunology, Inflammation and Infectious Diseases, Purdue University, West Lafayette, IN, USA</aff>
<aff id="A2"><label>2</label>
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA</aff>
<author-notes><corresp id="FN1"><label>*</label>
Correspondence: Suresh K. Mittal, Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA, Tel: 765-496-2894, Fax: 765-494-9830, <email>mittal@purdue.edu</email>
, Suryaprakash Sambhara, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, <email>ssambhara@cdc.gov</email>
</corresp>
<fn id="FN2" fn-type="present-address"><label>3</label>
<p id="P1">Present Address: Merck Sharp and Dohme, West Point, PA, USA</p>
</fn>
<fn id="FN3" fn-type="equal"><label>§</label>
<p id="P2">Contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>15</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub"><day>19</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub"><month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>01</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<issue>11</issue>
<fpage>1141</fpage>
<lpage>1154</lpage>
<pmc-comment>elocation-id from pubmed: 10.1080/14760584.2017.1379396</pmc-comment>
      <abstract><sec id="S1"><title>Introduction</title>
<p id="P3">Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of currently available influenza vaccines are strong inducer of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants.</p>
</sec>
<sec id="S2"><title>Areas covered</title>
<p id="P4">Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have potential to provide broad spectrum protection against influenza viruses.</p>
</sec>
<sec id="S3"><title>Expert opinion</title>
<p id="P5">Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.</p>
</sec>
</abstract>
<kwd-group><kwd>Influenza viruses</kwd>
<kwd>novel influenza vaccines</kwd>
<kwd>cross protection</kwd>
<kwd>pandemic influenza</kwd>
<kwd>universal influenza vaccine</kwd>
<kwd>pandemic preparedness</kwd>
<kwd>avian influenza viruses</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000825 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000825 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:6005355
   |texte=   Vaccine approaches conferring cross-protection against influenza viruses
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:28925296" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Vaccine approaches conferring cross-protection against influenza viruses

Vaccine approaches conferring cross-protection against influenza viruses

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki